Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New therapeutic approaches for advanced gastrointestinal stromal tumors.

Literature DB >> 19248977

New therapeutic approaches for advanced gastrointestinal stromal tumors.

Abstract

The management of advanced gastrointestinal stromal tumor is increasingly complex because of imatinib refractory disease. Primary resistance to imatinib is uncommon, and most patients progress after development of additional genetic changes. This article reviews management strategies including surgical approaches, local modalities for progressive liver metastases, as well as novel therapeutic agents.

Entities: CellLine Chemical Disease Gene Mutation Species

Mesh：

Year: 2009 PMID： 19248977 PMCID： PMC2861350 DOI： 10.1016/j.hoc.2008.12.004

Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN： 0889-8588 Impact factor: 3.722

38 in total

1. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Authors: Maria Debiec-Rychter; Raf Sciot; Axel Le Cesne; Marcus Schlemmer; Peter Hohenberger; Allan T van Oosterom; Jean-Yves Blay; Serge Leyvraz; Michel Stul; Paolo G Casali; John Zalcberg; Jaap Verweij; Martine Van Glabbeke; Anne Hagemeijer; Ian Judson
Journal: Eur J Cancer Date: 2006-04-18 Impact factor: 9.162

2. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT).

Authors: M Miettinen; L H Sobin; M Sarlomo-Rikala
Journal: Mod Pathol Date: 2000-10 Impact factor: 7.842

Review 3. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.

Authors: M Miettinen; J Lasota
Journal: Virchows Arch Date: 2001-01 Impact factor: 4.064

4. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.

Authors: Chandrajit P Raut; Matthew Posner; Jayesh Desai; Jeffrey A Morgan; Suzanne George; David Zahrieh; Christopher D M Fletcher; George D Demetri; Monica M Bertagnolli
Journal: J Clin Oncol Date: 2006-05-20 Impact factor: 44.544

5. Cellular origin of gastrointestinal stromal tumors: a study of 27 cases.

Authors: L Wang; H Vargas; S W French
Journal: Arch Pathol Lab Med Date: 2000-10 Impact factor: 5.534

6. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

Authors: Michael C Heinrich; Kouros Owzar; Christopher L Corless; Donna Hollis; Ernest C Borden; Christopher D M Fletcher; Christopher W Ryan; Margaret von Mehren; Charles D Blanke; Cathryn Rankin; Robert S Benjamin; Vivien H Bramwell; George D Demetri; Monica M Bertagnolli; Jonathan A Fletcher
Journal: J Clin Oncol Date: 2008-10-27 Impact factor: 44.544

7. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors: Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544

New therapeutic approaches for advanced gastrointestinal stromal tumors.

1. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

2. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT).

Review 3. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.

4. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.

5. Cellular origin of gastrointestinal stromal tumors: a study of 27 cases.

6. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

7. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

8. Molecular characterization of pediatric gastrointestinal stromal tumors.

9. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients.

10. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.

Review 1. Optimal use of targeted agents for advanced gastrointestinal stromal tumours.